MDGL
Madrigal Pharmaceuticals, Inc.
554.57
-5.98-1.07%
Dec 16, 4:00:00 PM EST

Upcoming Earnings 

Report date
-/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap
12.60B
P/E (TTM)
-
Basic EPS (TTM)
-12.92
Dividend Yield
0%

Recent Filings

About 

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

CEO
Mr. William J. Sibold
IPO
2/6/2007
Website
https://www.madrigalpharma.com
Employees
528
Sector
Healthcare
Industry
Biotechnology

Related Companies  

ALT
Altimmune, Inc.
5.03-0.25
GLMD
Galmed Pharmaceuticals Ltd.
0.98+0.01
GUTS
Fractyl Health, Inc.
2.16-0.08
IVA
Inventiva S.A. - American Depos
4.66+0.18
LGND
Ligand Pharmaceuticals Incorpor
192.63-0.25
MDWD
MediWound Ltd.
18.77-0.28
MNMD
Mind Medicine (MindMed) Inc.
12.26+0.18
MNOV
MediciNova, Inc.
1.48-0.04
MTSR
Metsera, Inc.
70.50-0.25
VRDN
Viridian Therapeutics, Inc.
32.85-0.18